These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21907082)

  • 1. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
    Prashanth LK; Fox S; Meissner WG
    Int Rev Neurobiol; 2011; 98():31-54. PubMed ID: 21907082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P; Konitsiotis S; Tagaris G; Peterson D;
    Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical approach to l-dopa-induced dyskinesias.
    Sankar T; Lozano AM
    Int Rev Neurobiol; 2011; 98():151-71. PubMed ID: 21907086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 12. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.
    Linazasoro G
    Trends Pharmacol Sci; 2005 Aug; 26(8):391-7. PubMed ID: 16009432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
    Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A
    Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classifying risk factors for dyskinesia in Parkinson's disease.
    Sharma JC; Bachmann CG; Linazasoro G
    Parkinsonism Relat Disord; 2010 Sep; 16(8):490-7. PubMed ID: 20598622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
    Blandini F
    Exp Neurol; 2003 Dec; 184(2):556-60. PubMed ID: 14769348
    [No Abstract]   [Full Text] [Related]  

  • 20. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
    Rice JE; Antic R; Thompson PD
    Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.